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Abstract
Objective—The objective of this study is to determine whether detection of HIV infection was 
delayed in infants exposed to antiretroviral prophylaxis to prevent HIV transmission during 
breastfeeding.
Design—The Breastfeeding, Antiretrovirals and Nutrition (BAN) study was a randomized trial of 
2369 mother–infant pairs conducted from 2004 to 2010. In addition to an intrapartum regimen, all 
mother–infant pairs were randomly assigned to three antiretroviral intervention arms during 28 
weeks of breastfeeding: no further antiretroviral prophylaxis (control arm); infant-daily nevirapine 
(nevirapine arm); and maternal zidovudine, lamivudine and either nevirapine, nelfinavir or 
lopinavir-ritonavir (maternal arm). After breastfeeding cessation counselling and stopping the 
antiretroviral interventions by 28 weeks, 28 infant HIV infections occurred.
Methods—To determine whether these infections occurred during the breastfeeding and 
antiretroviral intervention phase but had delayed detection on the antiretroviral arms, we 
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performed ultrasensitive (droplet digital PCR) HIV testing on infants with stored peripheral blood 
mononuclear cell (PBMC) specimens at 24 weeks (n = 9).
Results—Of the nine infants, all three on the infant nevirapine arm had detectable HIV DNA at 
24 weeks, compared with two of four on the maternal antiretroviral arm and one of two on the 
control arm. For infants with detectable HIV at 24 weeks, the median delay in detection between 
the ultrasensitive and standard assays was 18.3 weeks for the nevirapine arm, 15.4 weeks for the 
maternal arm and 9.4 weeks for the control arm.
Conclusion—The prolonged inability to detect HIV with standard assays in the context of 
postnatal antiretroviral prophylaxis suggests that early antiretrovirals may restrict HIV replication 
sufficiently to lead to missed diagnosis among infected infants. Therefore, repeat virologic testing 
is warranted beyond the WHO-recommended point of testing at 6 weeks after breastfeeding 
cessation.
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Introduction
Early detection and treatment of HIV type 1 infection among infants is essential to reduce 
their high risk of disease progression and mortality [1,2]. Very early initiation of 
combination antiretroviral therapy (ART) in the infant leads to rapid virologic control, 
limited seeding of replication-competent HIV reservoirs, reduced HIV quasispecies 
diversity, and in some cases, prolonged absence of HIV DNA detection, negative HIV 
serology and absence of HIV-specific humoral and cell-mediated immune responses [3–10]. 
However, early HIV detection depends on duration of the infection, assay sensitivity, 
specimen type, and potentially, the recommended use of antiretroviral prophylaxis by the 
HIV-infected mother or exposed infant [11]. There have been reports of delayed HIV DNA 
detection in nonbreastfeeding infants induced by 4–6 weeks of infant prophylaxis [12,13]. 
To our knowledge, no studies have assessed the effect of longer antiretroviral prophylaxis 
type or extent for breastfeeding infants on timing of HIV diagnosis. The WHO-
recommended duration of antiretroviral prophylaxis in settings in which breastfeeding is 
practiced extends to 1 week after breastfeeding cessation; breastfeeding is recommended for 
12 months for HIV-infected mothers in settings in which formula feeding is associated with 
an increased risk of morbidity and mortality [14].
Previously, we conducted a clinical trial of 2369 mother–infant pairs randomized to infant 
nevirapine, maternal antiretrovirals or neither during 28 weeks of breastfeeding [the 
Breastfeeding, Antiretrovirals and Nutrition (BAN) Study] [15]; both the infant and 
maternal prophylaxis significantly reduced HIV transmission during breastfeeding [16,17]. 
After breastfeeding cessation counselling and stopping the antiretroviral intervention by 28 
weeks postpartum, 28 infant infections were first detected during follow-up from 29 to 48 
weeks [17]. Although not statistically significant, more infections occurred on the infant 
nevirapine and maternal antiretroviral arms than on the control arm. To assess whether these 
infections occurred during the breastfeeding and antiretroviral intervention phase, but had 
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delayed detection on the antiretroviral intervention arms, we performed ultrasensitive HIV 
testing on stored peripheral blood mononuclear cell (PBMC) specimens.
Materials and methods
The BAN study was a randomized, controlled, clinical trial of 2369 mother–infant pairs 
enrolled in Lilongwe, Malawi, during the period 25 March 2004 to 28 January 2010 to 
investigate antiretroviral prevention of mother-to-child transmission of HIV-1 during 
breastfeeding (www.ClinicalTrials.govnumberNCT00164736) [15–17]. All mothers in 
labour and their newborn infants received a single dose of oral nevirapine and 7 days of 
Combivir (zidovudine, 300 mg, along with lamivudine, 150 mg) twice daily from the onset 
of labour for the mothers, and zidovudine (2 mg per kilogram of body weight) and 
lamivudine (4 mg per kilogram) twice daily for 7 days for the infants. Mother–infant pairs 
were randomly assigned to three antiretroviral intervention arms: no further antiretroviral 
prophylaxis (control arm); infants received a daily dose of nevirapine that increased 
according to age, ranging from10 mg daily during the first 2 weeks to 30 mg daily for weeks 
19 through 28; and mothers received Combivir (twice daily) and either nevirapine (200 mg) 
once daily for 2 weeks and twice daily through week 28, or nelfinavir (1250 mg) or Kaletra 
(lopinavir, 400 mg, along with ritonavir, 100 mg) twice daily through week 28. All 
antiretroviral interventions were stopped at 28 weeks postnatal or after reported 
breastfeeding cessation, whichever occurred first. In March 2008, the data safety monitoring 
board (DSMB) halted enrolment to the control arm after 668 of the planned 806 mother–
infant pairs had received control-arm assignment because the HIV transmission rate was 
significantly higher among the control group than one of the antiretroviral groups.
By using a standardized protocol derived from the WHO’s Breastfeeding Counselling: A 
Training Course [18], all mothers were individually counselled to breastfeed exclusively for 
the first 24 weeks postpartum, and then to wean from 24 to 28 weeks. Mothers were 
provided with breast milk replacement food for the infants. Internal validity checks for visits 
and forms were used to estimate a date of weaning for each mother–infant pair.
Mother–infant pairs were followed at 1, 2, 4, 6, 8, 12, 18, 21, 24, 28, 32, 36, 42 and 48 
weeks postpartum. The BAN Study protocol called for infant HIV testing on whole blood 
collected at birth, 2, 12, 28 and 48 weeks with Roche Amplicor HIV-1 Qualitative DNA 
assay, version 1.5 (Roche Molecular Systems, Pleasanton, California, USA). The test uses 
200 µl of infant blood and detects five copies of provirus 92% of the time [19]. Positive 
results were confirmed by tests of a second specimen. The window of HIV transmission was 
later narrowed by testing dry blood-spot (DBS) specimens from all interim visits for HIV 
DNA by using the Roche Amplicor DNA assay, or RNA by using the Gen-Probe Aptima 
HIV-1 assay, both performed at the University of North Carolina. Two 6 mm punches of 
DBS were used for an estimated volume of 40 µl for testing; the Roche DNA assay is 98.8% 
sensitive, and the Aptima RNA assay is 96.5% sensitive above 400 copies/ml in DBS [20]. 
PBMCs were collected at five infant visits and were cryopreserved at −80°C; midway 
through the study, such collection stopped to redirect resources [15].
King et al. Page 3













The BAN study was approved by the Malawi National Health Science Research Committee 
and institutional review boards at the University of North Carolina at Chapel Hill and the 
U.S. Centers for Disease Control and Prevention (CDC). All women provided written, 
informed consent for specimen storage and laboratory studies.
To determine whether the infant HIV infections after 28 weeks occurred during 
breastfeeding but had delayed detection on the antiretroviral arms, we performed 
ultrasensitive HIV testing on available infant PBMC specimens at 24 weeks. This time was 
chosen, as, per protocol, it represented the last study visit when the infant was still being 
exclusively breastfed. To exclude known ongoing exposure to HIV after 28 weeks, we 
excluded five infants whose reported breastfeeding cessation date was past the end of the 
antiretroviral intervention at 28 weeks. Of the remaining 23 infants, nine had available 
PBMC specimens at 24 weeks: three on the nevirapine arm, four on the maternal 
antiretroviral arm and two on the control arm. These nine HIV-infected infants, as well as 
three infants (one from each study arm) who remained HIV-negative by the end of the study 
follow-up at 48 weeks were blindly tested for HIV by using an ultrasensitive droplet digital 
PCR assay [21]. HIV and genomic DNA were extracted from frozen PBMC pellets by using 
QIAamp DNA Blood Mini Kit (Qiagen, Valencia, California, USA). The median number of 
cells per specimen was 376 200 (interquartile range: 188 650–502 250). HIV DNA was 
measured in six replicates by using ultrasensitive droplet digital PCR (ddPCR) (limit of 
detection ranging from 1.1 to 9.6 copies per million cells) [21]. Proviral burden was 
expressed as HIV DNA copies per million PBMCs.
The cumulative risk of infant HIV infection in BAN was estimated by an extension of the 
Kaplan–Meier method to account for the competing risk of infant death [22]. Infants who 
did not test HIV-positive or die were right censored at their last negative HIV test. 
Cumulative risk from 2 weeks to 28, 32, 36, 42 and 48 weeks was compared among arms on 
the basis of a two-sided P value for a Z statistic equal to the difference between the 
cumulative risk estimates at each time point divided by the corresponding estimated 
standard error. The median time between the ultrasensitive and standard assay’s detection of 
HIV DNA, as well as the median maternal viral load across trial arms, are presented. The 
exact Kruskal–Wallis test was used to estimate P values for the comparison of medians 
across trial arms despite low statistical power. For analyses limited to infants with detectable 
HIV DNA on the ultrasensitive assay, the minimal attainable P value based on a power 
calculation was 0.1 [23].
Results
In BAN, 28 incident infant HIV infections were identified from 29 to 48 weeks, after 
completion of the antiretroviral prophylaxis and breastfeeding period, as per the study 
protocol. Although not statistically significant, more infections were identified after 28 
weeks on the infant nevirapine (13/852) and maternal antiretroviral (nine of 849) arms than 
on the control arm (six of 668) (Fig. 1). However, the significantly increased cumulative risk 
of HIV infection at 28 weeks among infants on the control arm compared with the 
intervention arms reported previously [5.7% compared with 1.7% on the infant nevirapine 
arm (P<0.001) and 2.9% on the maternal antiretroviral (P = 0.02)] [17] remained 
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significantly increased at 32, 36, 42 and 48 weeks of life (Table 1). The largest incremental 
increase in cumulative incidence estimates of infant HIV risk after 28 weeks occurred from 
32 to 36 weeks on the infant nevirapine arm, with a 1.1% increase during this 4-week period 
compared with an incremental increase of 0.3 and 0.4% during the same 4-week period 
occurring on the maternal antiretroviral and control arms, respectively.
Of the nine infants with infections after 28 weeks tested with the ultrasensitive assay, all 
those on the infant nevirapine arm (three of three) had detectable HIV DNA at 24 weeks, 
compared with half of those on the maternal antiretroviral (two of four) and control (one of 
two) arms (Table 2). None of the three infants who remained HIV-negative by BAN testing 
through 48 weeks had a positive ddPCR test result. For the infants with detectable HIV at 24 
weeks, the median delay in detection between the ultrasensitive assay and the first positive 
BAN assay was 18.3 weeks on the nevirapine arm, 15.4 weeks on the maternal arm and 9.4 
weeks on the control arm (P = 0.267).
For the six infants with detectable HIV at 24 weeks, we tested a PBMC specimen from their 
12-week visit. However, four assays failed because of insufficient cells (n = 3) or failed 
ddPCR droplet formation (n = 1). Of the remaining two infants, one on the infant nevirapine 
arm had detectable DNA at 12 weeks (12.5 copies per million cells) and the other on the 
maternal antiretroviral arm did not. Including these two infants, the median delay in 
detection between the ultrasensitive and standard assays was 22.0 weeks on the infant 
nevirapine arm compared with 15.4 weeks on the maternal arm. Because of only having six 
infants to compare, the median delay in detection did not differ significantly by 
antiretroviral arm (P = 0.1).
There were no significant differences between the antiretroviral arms in adherence to the 
antiretroviral intervention or maternal viral load. All three mothers on the nevirapine arm 
reported complete adherence to the nevirapine regimen at all their reporting time points from 
1 to 21 weeks of age, and all four mothers on the maternal antiretroviral arm reported 
complete adherence to the HAART regimen at their reporting time points at 21 and 28 
weeks postpartum. There was no significant difference between the three study arms in 
median maternal log viral load at 24 weeks: 5.2 copies/ml on nevirapine arm, 3.7 copies/ml 
on the maternal antiretroviral arm and 5.1 copies/ml on the control arm (P = 0.76).
The infants and their mothers were evaluated for antiretroviral resistance mutations in HIV 
extracted from specimens collected at 48 weeks postpartum. Only one infant who was on the 
nevirapine arm had a resistance mutation, and it was the same as the mother’s (K103N), 
suggesting that the mutated virus was transmitted to the infant (Table 2). For the one infant 
on the control arm with detectable HIV at 24 weeks, we were unable to sufficiently amplify 
virus from dried blood spot specimens at 48 weeks to test for resistance mutations.
Discussion
By using an ultrasensitive assay, extremely low HIV DNA concentrations were detected in 
six of nine (66%) infants up to 31 weeks earlier than HIV detection by standard HIV testing. 
The delay between HIV detection on the ultrasensitive and standard assays was longest for 
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infants exposed to 28 weeks of infant nevirapine (median of 22 weeks, including the 12-
week positive result), of intermediate duration for infants on the maternal antiretroviral arm 
(15 weeks) and shortest for infants on the control arm (9 weeks). By using standard assays, 
other studies among nonbreastfed infants have reported shorter delays in HIV detection with 
use of 4–6 weeks of perinatal antiretroviral prophylaxis [12,13]. In one study, timing of HIV 
detectability in nonbreastfed infants was dependent on both the infant’s and mother’s receipt 
and duration of zidovudine prophylaxis [12]. Mothers with longer duration of antenatal 
zidovudine (7.5 weeks or more) were 2.7 times as likely to have an infant with an HIV 
infection only detectable after birth as at birth. If the mother received a shorter course of 
antenatal zidovudine, then infant zidovudine prophylaxis of 4 weeks or more was associated 
with HIV DNA detection at a median of 43 days postpartum compared with 11 days for 
infants on a short regimen of 3 days or less. In a pooled analysis of nonbreastfed HIV-
infected infants from several cohorts, the delay in HIV DNA positivity increased with 
potency of perinatal antiretrovirals [13]. The cumulative probabilities of the perinatally 
infected infants not being HIV DNA positive by 42 days were 6% for infants not on 
antiretrovirals, 9% for a single nucleoside reverse transcriptase inhibitor, 4% for single-dose 
nevirapine with and without zidovudine, and 21% for infants on three or more antiretrovirals 
[13]. In comparison, by 6 weeks from reported breastfeeding cessation in our study, all three 
infants on the nevirapine arm and three of four infants on the maternal antiretroviral arm 
were still HIV negative by the standard HIV assays. These findings suggest that the delay in 
HIV detection with prolonged antiretroviral prophylaxis during breastfeeding is longer than 
with perinatal prophylaxis.
The WHO recommends virologic testing of all HIV-exposed breastfeeding infants at 6 
weeks or more after breastfeeding cessation [11]. Testing at 6 weeks only would have failed 
to capture seven of the nine infants (78%) whose HIV infection was detected more than 6 
weeks after reported breastfeeding cessation by standard assays. Ultrasensitive testing or 
repeat virologic testing more than 6 weeks after breastfeeding and antiretroviral cessation 
may be warranted. Given the benefit of early diagnosis and treatment of infant HIV infection 
[7–9], some investigators have advocated for the use of combination ART for newborns of 
mothers with inadequately controlled HIV replication at delivery [9]. Although this 
approach may be ideal for infants who are HIV-infected, its potential for prolonged inability 
to detect HIV DNA with standard assays may complicate determination of infant HIV status 
and necessitate the use of ultrasensitive testing protocols or testing on larger blood volumes 
[24] before halting such prophylaxis. The current cost of the ultrasensitive assay and the fact 
that it is performed only in specialized laboratories restrict its clinical utility. However, as 
the ultrasensitive assay becomes more automated, we expect that it will become more 
widely used and clinically validated for diagnosis of HIV infection.
Our findings demonstrate much earlier HIV acquisition for many infants than that detected 
by standard testing. The fact that the delay in detecting HIV is longer when the infant 
received prophylaxis (either maternal or infant) suggests that the use of antiretrovirals may 
restrict HIV seeding of reservoirs and reduce reservoir size. Particular properties of 
antiretroviral drugs (such as half life and pharmacokinetic properties such as passage into 
breast-milk) may have different effects on the extent of such delay. The currently 
recommended by WHO first-line antiretroviral regimen during breastfeeding includes 
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efavirenz [14], whose pharmacokinetic properties differ from those of a protease inhibitor, 
used in our study. It is unknown whether the delays in infant HIV diagnosis may be even 
more prolonged with the currently recommended regimen.
The lack of de-novo development of nevirapine resistance in all three infants on the 
nevirapine arm who had HIV detected while continuing NVP prophylaxis for 4–17 weeks 
suggests limited active viral replication and possibly HIV ‘latency’. Together with the 
reports of viral rebound among adults and infants, even after prolonged viral suppression 
after antiretroviral discontinuation (e.g. the recent Mississippi infant) [25,26], these data 
indicate that HIV infection can remain latent for months and activate with the appropriate 
stimuli. Of interest, one infant on the control arm not receiving any antiretrovirals for 
prophylaxis had HIV detected 9 weeks before detection on the standard assay. Host and viral 
factors may contribute to the outcomes among different individuals. Our findings concur 
with those of other researchers who have shown that early initiation of ART restricts, but 
does not eliminate, latent infection of resting CD4+ T cells [5,27].
Another implication of our findings relates to the accuracy of reporting breastfeeding 
cessation by the mothers. Although in the absence of a biologic marker of breastfeeding, 
infant HIV infections acquired past the time of reported breastfeeding cessation might be 
attributed to continued unreported breastfeeding, our findings of earlier HIV detection 
during known breastfeeding challenge this assumption.
The primary limitation of this analysis is the small number of infants infected after 28 weeks 
with available cryopreserved PBMC at appropriate time points for testing with the 
ultrasensitive assay. Another limitation is blood volume restrictions among young infants, 
which limits the number of cells for our virus assay. This precluded amplification and 
sequencing of the virus to verify genetic linkage between the virus detected on ultrasensitive 
assay and that detected by standard BAN testing. Despite this, it seems unlikely that 
contamination occurred because all assays were performed in a CLIA-compliant laboratory, 
and the detection or absence of HIV DNA was consistent across repeat ultrasensitive assays 
on separate PBMC samples, when available (n = 6 infants). Another limitation to the 
interpretation of our study findings is that the estimates of delayed detection are interval 
censored because of HIV testing at study visits scheduled 4–6 weeks apart. Despite this, 
only one of the infants (on the infant nevirapine arm) was missing a single interim HIV 
assay between their last negative and first positive BAN assay. Furthermore, the study HIV 
tests were performed on whole blood only at 2, 12, 28 and 48 weeks, with HIV testing at the 
remaining interim visits performed on DBS. However, the frequent occurrence of first HIV 
detection on DBS (seven out of nine infants) and the short time frame between the detection 
of some infant HIV infections on DBS and last HIV-negative test on whole blood (4 weeks 
for those detected at 32 weeks) suggests that there was not much loss in HIV sensitivity of 
the assay on the basis of the type of specimen tested.
In conclusion, in the context of postnatal antiretroviral prophylaxis, the prolonged inability 
to detect HIV DNA on standard assays suggests that antiretroviral prophylaxis may keep 
HIV infection ‘latent’, in some cases for months, but not necessarily prevent its 
establishment. In addition, this conclusion may apply to other categories of preexposure 
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prophylaxis, beyond infancy. Our findings also suggest that repeated virologic testing 
beyond the WHO-recommended earliest point for HIV testing at 6 weeks after breastfeeding 
cessation is warranted to detect HIV infections in infants. Although the benefit of extending 
the duration of antiretroviral prophylaxis longer past cessation of HIV exposure, or 
intensifying antiretroviral prophylaxis during exposure, may need to be tested for their 
potential to augment prevention of transmission, our data suggest that antiretroviral 
approaches may not be enough to achieve elimination of transmission. Other novel strategies 
targeting the rare cellular reservoirs or boosting the immune system’s response may be 
necessary to achieve this goal. Ultrasensitive testing may allow for earlier antiretroviral 
treatment, which might modify establishment of HIV reservoirs, and its role in future testing 
strategies will need to be evaluated with advances in its automation and performance [5].
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Fig. 1. Antiretroviral interventionsa, HIV testing time pointsb and infant HIV infection 
outcomes in the Breastfeeding, Antiretrovirals and Nutrition Study, Malawi 2004–2010
aMother–infant pairs were randomized to 3 antiretroviral intervention arms: Maternal ARV 
[zidovudine, lamivudine and either nevirapine (n = 39), nelfinavir (n = 146) or lopinavir-
ritonavir (n = 664)]; infant nevirapine (daily infant nevirapine with dosage increasing with 
age); and enhanced control (mothers and infants received only the 7-day intrapartum 
regimen provided to all BAN participants). bThe BAN Study protocol called for infant HIV 
testing on whole blood collected at birth, 2, 12, 28 and 48 weeks. The window of 
seroconversion was later narrowed by testing dried blood spots from all interim visits 
shown. Infants infected by 2 weeks of age were excluded from counts of HIV infections to 
minimize counting of in-utero/peripartum infections.
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